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poA-IMilano/Phospholipid
omplex
linical Implications of Dose-Response
tudies in Rabbit Atherosclerosis
ith Intravascular Ultrasound
nd Magnetic Resonance Imaging*
ue-Qiao Zhao, MD, B. Greg Brown, MD, PHD
eattle, Washington
arolini et al. (1) report in this issue of the Journal on the
ffects of recombinant apoA-IMilano/1-palmitoyl-2-oleoyl
hosphatidylcholine complexes (ETC-216) on injury-
nduced carotid atherosclerotic plaques in cholesterol-fed
ew Zealand White rabbits (2). The rabbits received 1 of 5
ifferent intravenous doses (5, 10, 20, 40, or 150 mg/kg) of
TC-216 or placebo every 4 days for 5 infusions. Intravas-
ular ultrasound was used to measure carotid atheroma
olume at baseline and after the final infusion. Contrast-
nhanced magnetic resonance imaging (MRI) was per-
ormed before treatment and after infusion of the second
nd fifth dose of placebo, 40 or 150 mg/kg.
See pages 1098 and 1104
This dose-finding study demonstrated significant plaque
egression, about 6%, in ETC-216–treated rabbits com-
ared with placebo with each technique. The minimally
ffective dose was 40 mg/kg. The rapid-onset effective dose
as 150 mg/kg. Five infusions seemed to be necessary. The
uthors of this study partially confirmed previous ETC-
16–induced plaque regression (3,4). However, they did not
se MRI’s tissue-composition capabilities (5,6) to document
he mechanism of shrinkage.
A similar report by Ibanez et al. (7) asks whether ETC-216
nfusions acutely change plaque size, cell morphology, or
xpression of genes and proteins, potentially contributing to
laque vulnerability. In a similar aortic injury model of ad-
anced atherosclerosis, rabbits were randomized to 2 infusions,
eparated by 4 days, of 75 mg/kg ETC-216 or placebo. Aortic
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, Cardiology Division, University of Washing-p
on, School of Medicine, Seattle, Washington. Supported in part by NIH Grants R01
L063895 and R01 HL088214.laques (celiac to iliac level) were imaged withMRI before and
fter the infusions, and their area was measured with the use of
emiautomated visual border-definition. Aortic cellular com-
osition and gene expression markers were subsequently as-
essed histologically. Relative to placebo, which had no effect,
TC-216 infusions reduced mean plaque area by 5% from
re-treatment (p 0.003). This effect compares to a previously
eported 12% (p  0.05) and 22% (p  0.01) plaque area
eduction in this model after 6 months treatment with simva-
tatin  a peroxisomal proliferator-activated receptor-gamma
gent (8), and to 4% coronary plaque reduction in patients (9).
acrophage density and gene and protein expression of tissue
actor, monocyte chemoattractant protein–1, cyclooxygenase-2,
nd gelatinase, all putative markers of plaque vulnerability, were
easurably reduced.
These 2 studies found consistent and significant plaque
egression, approximately 6%, in ETC-216–treated animals,
ompared with placebo. The plaque regression was assessed by
different and reliable imaging modalities (intravascular ultra-
ound and MRI) in both carotids and aortas. Favorable
hanges in plaque area and in markers of vulnerability were
bserved after only 2 administrations of ETC-216. These
esults support the idea that these infusions are rapidly effective
n modestly reducing atherosclerosis burden.
A crucial question is whether the 6% plaque regression
ound in these 2 studies is biologically or clinically meaningful.
xperimental atherosclerosis in rabbits differs markedly from
uman plaques. The rabbits’ atherosclerosis, induced over
everal months, comprises nearly 90% cholesterol-enriched
oam cells (2) that are more easily lipid-depleted (10). How-
ver, removable plaque components (lipid) represent only 13%
o 16% of the average human plaque (11). Thus, human plaque
olume is probably less responsive to ETC-216, to be consid-
red in planning future human studies.
If this amount of plaque shrinkage is due to reductions in
laque core lipid, foam cell density, and inflammatory
ctivities, this should benefit clinical outcomes, because 60%
o 90% of unstable clinical episodes are due to disruption
nd thrombosis of lipid-rich plaques, which represent ap-
roximately 15% of human coronary lesions (50% lipid by
olume) (12,13). Long-term intensive lipid therapy is asso-
iated with markedly, and selectively, reduced plaque lipid
ontent assessed by MRI (14). These patients also have
ignificantly reduced cardiovascular death and myocardial
nfarction frequency compared with those given usual care
15). Other lipid therapy trials that use quantitative arte-
iography (16–18) have demonstrated that coronary disease
egression is correlated with a reduction in low-density
ipoprotein cholesterol, an increase in high-density lipopro-
ein (HDL) cholesterol, and with a reduction in coronary
vents. If the authors of these 2 studies (1,7) had used
RI’s capability to resolve tissue composition, they might
ave confirmed that the 6% regression was entirely due to
laque lipid depletion.
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March 18, 2008:1110–1 Editorial CommentAnother critical question is whether partially delipidated
omologous or even autologous apolipoprotein (apo) A-I or a
ynthetic nascent HDL particle (2 apoA-I molecules bound by
hospholipids) or oral apoA-I-mimetic peptides (19) would
ork as well as the ETC-216 particle for depletion of plaque
ipid or inhibition of inflammation (20) or of endothelial cell
dhesion molecules (21). However, the unique molecular
tructure of apoA-IMilano (22) may convey unique properties.
espite very low HDL cholesterol levels, apoA-IMilano carriers
o not display features of impaired vascular function, such as
levated levels of soluble cell adhesion molecules, increased
umor necrosis factor-, or reduced endothelial nitric oxide
ynthase expression (23), and they do not demonstrate the
nticipated cardiovascular complications (24).
Finally, because of cost, inconvenience, and possible
ntigenic effects, it is highly unlikely that chronic apoAI/
hospholipid infusions would substitute for lipid drug
herapy as a chronic prevention strategy. If, however, the
mmediate clinical benefits of acute apoAI infusions are
stablished in phase-3 trials, with a defined agent, dose, and
osing sequence, then such infusions would most likely be
sed in the early aftermath of an acute coronary syndrome
ACS). During the first 6 to 8 months after ACS, the coronary
vent rate is at least twice as great as that in the subsequent
hronic follow-up period (25,26). If apoAI infusions are
ound to deplete plaque lipid and to stabilize vulnerable
laque more rapidly and effectively than the current stan-
ard post-ACS therapy, then this approach, as an adjunctive
o pharmacologic lipid-altering therapy, may have merit.
n the basis of these 2 reports (1,7), the likely regimen will
e the human equivalent of the 40- to 75-mg/kg rabbit
ose, administered 4 to 5 times at plasma half-life intervals.
ethods for more selective delivery may be developed.
uch work remains.
eprint requests and correspondence: Dr. Xue-Qiao Zhao,
niversity of Washington, 1914 North 34th Street, Suite 204,
eattle, Washington 98103. E-mail: xueqiao@u.washington.edu.
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